PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease

Medicine & Life Sciences

1. Parkinson Disease 100%
2. Pituitary Adenylate Cyclase-Activating Polypeptide 92%
3. Glycopeptides 66%
4. Vasoactive Intestinal Peptide 61%
5. Intercellular Signaling Peptides and Proteins 43%
6. Brain 32%
7. Neuroprotection 27%
8. Dopaminergic Neurons 27%
9. Blood-Brain Barrier 25%
10. Dopamine 22%
11. Receptors, Vasoactive Intestinal Peptide, Type II 22%
12. Receptors, Vasoactive Intestinal Polypeptide, Type I 21%
13. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I 21%
14. Animal Models 19%
15. Drug Stability 18%
16. Secretin 16%
17. CHO Cells 15%
18. Immunomodulation 15%
19. Firearms 15%
20. Microdialysis 14%
21. Surface-Active Agents 13%
22. Drug Development 12%
23. Mass Spectrometry 11%
24. Walking 11%
25. Neurodegenerative Diseases 11%
26. Rodentia 10%
27. Pharmaceutical Preparations 10%
28. Technology 8%
29. Clinical Trials 8%
30. Peptides 8%
31. Inflammation 7%
32. Therapeutics 6%